NCT00219219已完成4 期
Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Novartis
- 试验地点
- 1
- 主要终点
- occurence of skeletale related events (SREs) over time (time to first SRE,skeletal morbidity rate and proportion of patients experiencing SRE)
研究概览
简要总结
The present study will give information about the course over time in skeletal-related events (SRE) in prostate cancer patients with bone metastases treated with zoledronic acid 4 mg administered as a 15-minute infusion every 4 weeks for a maximum of 15 infusions. The protocol will enroll patients with recent diagnosis of bone metastases from prostate cancer who are hormone-refractory, hormone-naïve or still hormone-sensitive, that represent the entire population of prostate cancer patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients aged ≥18 years
- •Written informed consent
- •Histologically-proven prostate carcinoma
- •ECOG performance status ≤ 2
- •Life expectancy > 6 months
- •Newly diagnosed (≤ 6 months prior to visit 1) bone metastases evidenced by bone scan or radiograph.
- •Patients on androgen deprivation therapy (medical therapy with LHRH analogues + antiandrogens or surgical castration) or going to start it
- •Patients with partners of childbearing potential should use a barrier method of contraception throughout the study
排除标准
- •Patients without a history of metastatic disease to the bone
- •Prior treatment with bisphosphonates
- •SREs prior to visit 2
- •Prior treatment with calcitonin, mithramycin, or gallium nitrate within 2 weeks prior to baseline
- •Corrected (adjusted for serum albumin - see Appendix 5 for the calculation) serum calcium concentration < 8.0 mg/dl (2.00 mmol/l)
- •Serum creatinine concentration > 265 micromol/l (3.0 mg/dl) or a calculated creatinine clearance < 30 ml/minute or serious underlying renal disease or prior renal transplantation
- •History of other malignant neoplasm within previous five years with exception of non-melanomatous skin cancer which has been satisfactorily treated
- •Other known concurrent, severe medical disorder jeopardizing the life of the patient in the immediate future
- •Patients treated with systemic investigational drug(s) and/or device(s) within the past 30 days or topical investigational drugs within the past 7 days
- •Known hypersensitivity to zoledronic acid or other bisphosphonates
- •History of noncompliance to medical regimens and patients who are considered potentially unreliable (for example drug or alchohol abusers) or incapable of giving informed consent as judged by the investigator
结局指标
主要结局
occurence of skeletale related events (SREs) over time (time to first SRE,skeletal morbidity rate and proportion of patients experiencing SRE)
次要结局
- Bone pain
- Use of analgesic medication and ECOG performance status every three months
- Bone specific alkaline phosphatase, serum N-telopeptide and parathyroid hormone will be evaluated after one month of treatment and then every three months
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone MetastasisRenal Cell CancerNeoplasm MetastasisNCT00172003Novartis Pharmaceuticals50
尚未招募
不适用
Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective, Multicenter, Real-world StudyHistologically Confirmed Breast Cancer ,Diagnosis of Bone MetastasisNCT05480189Zhejiang Cancer Hospital1,000
Unknown
不适用
Effect of Zoledronic Acid on Prevention of Bone Loss in Acute Phase First-ever Stroke PatientsStrokeNCT04652128Yonsei University56
已完成
2 期
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate CancerBone LossProstate CancerNCT00181584Massachusetts General Hospital60
已完成
4 期
Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric SurgeryBariatric Surgery CandidateNCT03424239Massachusetts General Hospital6